Wednesday, September 02
Mumbai|New Delhi: The commerce ministry and the ministry of health are in extensive deliberations over the issue of inclusion of data exclusivity or protection provisions in the proposed drug regulatory and legal framework, senior industry officials told ET.The matter has gained prominence in the last few weeks amid extensive lobbying by domestic drug industry groups, civil society, patient advocacy groups, and pharma multinationals. All the concerned parties made opposing claims to senior officials in the ministries on how data protection provisions could impact access to lifesaving drugs for Indian patients."An inter-departmental secretary level meeting was held recently but there was no consensus," one of the officials said. "There is a positive indication on the acceptance of data prot
Kolkata: Top Chinese electronic brands in India such as Oppo, Vivo, Lenovo-Motorola, Haier and Midea are funding their India businesses through borrowings from group entities, as per the latest Registrar of Companies filings. That’s due to lack of Press Note 3 (PN3) approval for equity funding and regulatory action against some of them, making accessibility to local bank loans a challenge, said people familiar with the matter.Most of the funding is through the external commercial borrowing (ECB) route from related parties. Till PN3 regulations came into force, these entities funded Indian operations through equity capital. PN3 regulations effective 2020 barred foreign direct investment (FDI) through the automatic route for companies headquartered in neighbouring countries such as China.
